Dendritic Cell Therapies for Hematologic Malignancies

Molecular Therapy Methods and Clinical Development

Volumn 5, Issue , 2017, Pages 66-75

  Weinstock, Matthew ^a   Rosenblatt, Jacalyn ^a   Avigan, David ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

AML; cancer immunotherapy; dendritic cell; multiple myeloma; tumor immunology; vaccine

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; TUMOR ANTIGEN;

ACUTE MYELOID LEUKEMIA; ANTIGEN FUNCTION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DENDRITIC CELL SARCOMA; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; VACCINE PRODUCTION; WHOLE CELL;

EID: 85017037031     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1016/j.omtm.2017.03.004     Document Type: Review

References (97)

1. 1 Mellman, I., Steinman, R.M., Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001), 255–258.
2. 2 Dieu-Nosjean, M.C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., Rabbe, N., Laurans, L., Tartour, E., de Chaisemartin, L., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26 (2008), 4410–4417.
3. 3 Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
4. 4 Lim, T.S., Chew, V., Sieow, J.L., Goh, S., Yeong, J.P., Soon, A.L., Ricciardi-Castagnoli, P., PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. OncoImmunology, 5, 2015, e1085146.
5. 5 Choe, J.Y., Yun, J.Y., Jeon, Y.K., Kim, S.H., Park, G., Huh, J.R., Oh, S., Kim, J.E., Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer, 14, 2014, 335.
6. 6 Caux, C., Vanbervliet, B., Massacrier, C., Azuma, M., Okumura, K., Lanier, L.L., Banchereau, J., B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180 (1994), 1841–1847.
7. 7 Jung, S., Unutmaz, D., Wong, P., Sano, G., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17 (2002), 211–220.
8. 8 Batchu, R.B., Moreno, A.M., Szmania, S.M., Bennett, G., Spagnoli, G.C., Ponnazhagan, S., Barlogie, B., Tricot, G., van Rhee, F., Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res. 65 (2005), 10041–10049.
9. 9 Dadabayev, A.R., Wang, Z., Zhang, Y., Zhang, J., Robinson, W.R., Lim, S.H., Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics?. Am. J. Hematol. 80 (2005), 6–11.
10. 10 Koido, S., Enomoto, Y., Apostolopoulos, V., Gong, J., Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines. Anticancer Res. 34 (2014), 3917–3924.
11. 11 Carpenter, R.O., Evbuomwan, M.O., Pittaluga, S., Rose, J.J., Raffeld, M., Yang, S., Gress, R.E., Hakim, F.T., Kochenderfer, J.N., B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19 (2013), 2048–2060.
12. 12 Yi, Q., Szmania, S., Freeman, J., Qian, J., Rosen, N.A., Viswamitra, S., Cottler-Fox, M., Barlogie, B., Tricot, G., van Rhee, F., Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br. J. Haematol. 150 (2010), 554–564.
13. 13 Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., Linette, G.P., Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808.
14. 14 Liggins, A.P., Lim, S.H., Soilleux, E.J., Pulford, K., Banham, A.H., A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun., 10, 2010, 8.
15. 15 Dhodapkar, M.V., Osman, K., Teruya-Feldstein, J., Filippa, D., Hedvat, C.V., Iversen, K., Kolb, D., Geller, M.D., Hassoun, H., Kewalramani, T., et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun., 3, 2003, 9.
16. 16 Jungbluth, A.A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y.T., Bhardwaj, N., Chen-Kiang, S., Old, L.J., Cho, H.J., The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106 (2005), 167–174.
17. 17 Taylor, B.J., Reiman, T., Pittman, J.A., Keats, J.J., de Bruijn, D.R., Mant, M.J., Belch, A.R., Pilarski, L.M., SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J. Immunother. 28 (2005), 564–575.
18. 18 Srivastava, P., Paluch, B.E., Matsuzaki, J., James, S.R., Collamat-Lai, G., Blagitko-Dorfs, N., Ford, L.A., Naqash, R., Lübbert, M., Karpf, A.R., et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget 7 (2016), 12840–12856.
19. 19 Dubovsky, J.A., McNeel, D.G., Powers, J.J., Gordon, J., Sotomayor, E.M., Pinilla-Ibarz, J.A., Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin. Cancer Res. 15 (2009), 3406–3415.
20. 20 Bol, K.F., Tel, J., de Vries, I.J., Figdor, C.G., Naturally circulating dendritic cells to vaccinate cancer patients. OncoImmunology, 2, 2013, e23431.
21. 21 van Broekhoven, C.L., Parish, C.R., Demangel, C., Britton, W.J., Altin, J.G., Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64 (2004), 4357–4365.
22. 22 Curti, A., Isidori, A., Ferri, E., Terragna, C., Neyroz, P., Cellini, C., Ratta, M., Baccarani, M., Lemoli, R.M., Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk. Lymphoma 45 (2004), 1419–1428.
23. 23 Collin, M., McGovern, N., Haniffa, M., Human dendritic cell subsets. Immunology 140 (2013), 22–30.
24. 24 Dudziak, D., Kamphorst, A.O., Heidkamp, G.F., Buchholz, V.R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.W., Park, C.G., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315 (2007), 107–111.
25. 25 Mohamadzadeh, M., Olson, S., Kalina, W.V., Ruthel, G., Demmin, G.L., Warfield, K.L., Bavari, S., Klaenhammer, T.R., Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. USA 102 (2005), 2880–2885.
26. 26 Gori, S., Vermeulen, M., Remes-Lenicov, F., Jancic, C., Scordo, W., Ceballos, A., Towstyka, N., Bestach, Y., Belli, C., Sabbione, F., et al. Acetylcholine polarizes dendritic cells toward a Th2-promoting profile. Allergy 72 (2017), 221–231.
27. 27 Linehan, J.L., Dileepan, T., Kashem, S.W., Kaplan, D.H., Cleary, P., Jenkins, M.K., Generation of Th17 cells in response to intranasal infection requires TGF-β1 from dendritic cells and IL-6 from CD301b+ dendritic cells. Proc. Natl. Acad. Sci. USA 112 (2015), 12782–12787.
28. 28 George, M.M., Subramanian Vignesh, K., Landero Figueroa, J.A., Caruso, J.A., Deepe, G.S. Jr., Zinc induces dendritic cell tolerogenic phenotype and skews regulatory T cell-Th17 balance. J. Immunol. 197 (2016), 1864–1876.
29. 29 Ratzinger, G., Baggers, J., de Cos, M.A., Yuan, J., Dao, T., Reagan, J.L., Münz, C., Heller, G., Young, J.W., Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J. Immunol. 173 (2004), 2780–2791.
30. 30 Chung, D.J., Romano, E., Pronschinske, K.B., Shyer, J.A., Mennecozzi, M., St Angelo, E.T., Young, J.W., Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy. J. Transl. Med., 11, 2013, 166.
31. 31 Romano, E., Cotari, J.W., Barreira da Silva, R., Betts, B.C., Chung, D.J., Avogadri, F., Fink, M.J., St Angelo, E.T., Mehrara, B., Heller, G., et al. Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood 119 (2012), 5182–5190.
32. 32 Ueno, H., Tcherepanova, I., Reygrobellet, O., Laughner, E., Ventura, C., Palucka, A.K., Banchereau, J., Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J. Immunol. Methods 285 (2004), 171–180.
33. 33 Banchereau, J., Palucka, A.K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K.M., Bhardwaj, N., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61 (2001), 6451–6458.
34. 34 Palucka, A.K., Dhodapkar, M.V., Paczesny, S., Burkeholder, S., Wittkowski, K.M., Steinman, R.M., Fay, J., Banchereau, J., Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J. Immunother. 26 (2003), 432–439.
35. 35 Palucka, A.K., Dhodapkar, M.V., Paczesny, S., Ueno, H., Fay, J., Banchereau, J., Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J. Immunother. 28 (2005), 158–168.
36. 36 Meyer-Wentrup, F., Benitez-Ribas, D., Tacken, P.J., Punt, C.J., Figdor, C.G., de Vries, I.J., Adema, G.J., Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 111 (2008), 4245–4253.
37. 37 Dzionek, A., Sohma, Y., Nagafune, J., Cella, M., Colonna, M., Facchetti, F., Günther, G., Johnston, I., Lanzavecchia, A., Nagasaka, T., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J. Exp. Med. 194 (2001), 1823–1834.
38. 38 Matta, B.M., Castellaneta, A., Thomson, A.W., Tolerogenic plasmacytoid DC. Eur. J. Immunol. 40 (2010), 2667–2676.
39. 39 Krug, A., Towarowski, A., Britsch, S., Rothenfusser, S., Hornung, V., Bals, R., Giese, T., Engelmann, H., Endres, S., Krieg, A.M., Hartmann, G., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31 (2001), 3026–3037.
40. 40 González, F.E., Gleisner, A., Falcón-Beas, F., Osorio, F., López, M.N., Salazar-Onfray, F., Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum. Vaccin. Immunother. 10 (2014), 3261–3269.
41. 41 Hong, S., Li, H., Qian, J., Yang, J., Lu, Y., Yi, Q., Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin. Exp. Immunol. 170 (2012), 167–177.
42. 42 Spisek, R., Chevallier, P., Morineau, N., Milpied, N., Avet-Loiseau, H., Harousseau, J.L., Meflah, K., Gregoire, M., Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 62 (2002), 2861–2868.
43. 43 Kokhaei, P., Choudhury, A., Mahdian, R., Lundin, J., Moshfegh, A., Osterborg, A., Mellstedt, H., Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 18 (2004), 1810–1815.
44. 44 Hao, S., Bai, O., Li, F., Yuan, J., Laferte, S., Xiang, J., Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 120 (2007), 90–102.
45. 45 Näslund, T.I., Gehrmann, U., Qazi, K.R., Karlsson, M.C., Gabrielsson, S., Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol. 190 (2013), 2712–2719.
46. 46 Milazzo, C., Reichardt, V.L., Müller, M.R., Grünebach, F., Brossart, P., Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101 (2003), 977–982.
47. 47 Galea-Lauri, J., Darling, D., Mufti, G., Harrison, P., Farzaneh, F., Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51 (2002), 299–310.
48. 48 Parkhurst, M.R., DePan, C., Riley, J.P., Rosenberg, S.A., Shu, S., Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. Immunol. 170 (2003), 5317–5325.
49. 49 Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi, B., Engleman, E.G., Levy, R., Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2 (1996), 52–58.
50. 50 Timmerman, J.M., Czerwinski, D.K., Davis, T.A., Hsu, F.J., Benike, C., Hao, Z.M., Taidi, B., Rajapaksa, R., Caspar, C.B., Okada, C.Y., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 (2002), 1517–1526.
51. 51 Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5 (1999), 1171–1177.
52. 52 Barrios, Y., Cabrera, R., Yáñez, R., Briz, M., Plaza, A., Forés, R., Fernández, M.N., Díaz-Espada, F., Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87 (2002), 400–407.
53. 53 Neelapu, S.S., Baskar, S., Gause, B.L., Kobrin, C.B., Watson, T.M., Frye, A.R., Pennington, R., Harvey, L., Jaffe, E.S., Robb, R.J., et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res. 10 (2004), 8309–8317.
54. 54 Inogès, S., Rodrìguez-Calvillo, M., Zabalegui, N., Lòpez-Dìaz de Cerio, A., Villanueva, H., Soria, E., Suárez, L., Rodríguez-Caballero, A., Pastor, F., García-Muñóz, R., et al. Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl. Cancer Inst. 98 (2006), 1292–1301.
55. 55 Bertinetti, C., Zirlik, K., Heining-Mikesch, K., Ihorst, G., Dierbach, H., Waller, C.F., Veelken, H., Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. 66 (2006), 4496–4502.
56. 56 Freedman, A., Neelapu, S.S., Nichols, C., Robertson, M.J., Djulbegovic, B., Winter, J.N., Bender, J.F., Gold, D.P., Ghalie, R.G., Stewart, M.E., et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27 (2009), 3036–3043.
57. 57 Schuster, S.J., Neelapu, S.S., Gause, B.L., Janik, J.E., Muggia, F.M., Gockerman, J.P., Winter, J.N., Flowers, C.R., Nikcevich, D.A., Sotomayor, E.M., et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29 (2011), 2787–2794.
58. 58 Levy, R., Ganjoo, K.N., Leonard, J.P., Vose, J.M., Flinn, I.W., Ambinder, R.F., Connors, J.M., Berinstein, N.L., Belch, A.R., Bartlett, N.L., et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J. Clin. Oncol. 32 (2014), 1797–1803.
59. 59 Di Nicola, M., Zappasodi, R., Carlo-Stella, C., Mortarini, R., Pupa, S.M., Magni, M., Devizzi, L., Matteucci, P., Baldassari, P., Ravagnani, F., et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 113 (2009), 18–27.
60. 60 Ossenkoppele, G.J., Stam, A.G., Westers, T.M., de Gruijl, T.D., Janssen, J.J., van de Loosdrecht, A.A., Scheper, R.J., Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17 (2003), 1424–1426.
61. 61 Litzow, M.R., Dietz, A.B., Bulur, P.A., Butler, G.W., Gastineau, D.A., Hoering, A., Fink, S.R., Letendre, L., Padley, D.J., Paternoster, S.F., et al. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 8 (2006), 290–298.
62. 62 Westermann, J., Kopp, J., van Lessen, A., Hecker, A.C., Baskaynak, G., le Coutre, P., Döhner, K., Döhner, H., Dörken, B., Pezzutto, A., Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br. J. Haematol. 137 (2007), 297–306.
63. 63 Hus, I., Roliński, J., Tabarkiewicz, J., Wojas, K., Bojarska-Junak, A., Greiner, J., Giannopoulos, K., Dmoszyńska, A., Schmitt, M., Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19 (2005), 1621–1627.
64. 64 Hus, I., Schmitt, M., Tabarkiewicz, J., Radej, S., Wojas, K., Bojarska-Junak, A., Schmitt, A., Giannopoulos, K., Dmoszyńska, A., Roliński, J., Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22 (2008), 1007–1017.
65. 65 Palma, M., Hansson, L., Choudhury, A., Näsman-Glaser, B., Eriksson, I., Adamson, L., Rossmann, E., Widén, K., Horváth, R., Kokhaei, P., et al. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunol. Immunother. 61 (2012), 865–879.
66. 66 Suehiro, Y., Hasegawa, A., Iino, T., Sasada, A., Watanabe, N., Matsuoka, M., Takamori, A., Tanosaki, R., Utsunomiya, A., Choi, I., et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br. J. Haematol. 169 (2015), 356–367.
67. 67 Reichardt, V.L., Okada, C.Y., Liso, A., Benike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume, K.G., Levy, R., Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93 (1999), 2411–2419.
68. 68 Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94 (1999), 673–683.
69. 69 Lim, S.H., Bailey-Wood, R., Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 83 (1999), 215–222.
70. 70 Cull, G., Durrant, L., Stainer, C., Haynes, A., Russell, N., Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br. J. Haematol. 107 (1999), 648–655.
71. 71 Titzer, S., Christensen, O., Manzke, O., Tesch, H., Wolf, J., Emmerich, B., Carsten, C., Diehl, V., Bohlen, H., Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. 108 (2000), 805–816.
72. 72 Yi, Q., Desikan, R., Barlogie, B., Munshi, N., Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br. J. Haematol. 117 (2002), 297–305.
73. 73 Liso, A., Stockerl-Goldstein, K.E., Auffermann-Gretzinger, S., Benike, C.J., Reichardt, V., van Beckhoven, A., Rajapaksa, R., Engleman, E.G., Blume, K.G., Levy, R., Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6 (2000), 621–627.
74. 74 Röllig, C., Schmidt, C., Bornhäuser, M., Ehninger, G., Schmitz, M., Auffermann-Gretzinger, S., Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J. Immunother. 34 (2011), 100–106.
75. 75 Lacy, M.Q., Mandrekar, S., Dispenzieri, A., Hayman, S., Kumar, S., Buadi, F., Dingli, D., Litzow, M., Wettstein, P., Padley, D., et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am. J. Hematol. 84 (2009), 799–802.
76. 76 Hobo, W., Strobbe, L., Maas, F., Fredrix, H., Greupink-Draaisma, A., Esendam, B., de Witte, T., Preijers, F., Levenga, H., van Rees, B., et al. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol. Immunother. 62 (2013), 1381–1392.
77. 77 Rosenblatt, J., Vasir, B., Uhl, L., Blotta, S., Macnamara, C., Somaiya, P., Wu, Z., Joyce, R., Levine, J.D., Dombagoda, D., et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117 (2011), 393–402.
78. 78 Rosenblatt, J., Avivi, I., Vasir, B., Uhl, L., Munshi, N.C., Katz, T., Dey, B.R., Somaiya, P., Mills, H., Campigotto, F., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19 (2013), 3640–3648.
79. 79 Clinical Trials.gov. (2016). Dendritic cell/myeloma fusion vaccine for multiple myeloma (BMT CTN 1401). https://clinicaltrials.gov/ct2/show/NCT02728102.
80. 80 Rosenblatt, J., Glotzbecker, B., Mills, H., Vasir, B., Tzachanis, D., Levine, J.D., Joyce, R.M., Wellenstein, K., Keefe, W., Schickler, M., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34 (2011), 409–418.
81. 81 Clinical Trials.gov. (2016). Survivin vaccine: multiple myeloma autologous hematopoietic cell transplant (HCT). https://clinicaltrials.gov/ct2/show/NCT02851056.
82. 82 Clinical Trials.gov. (2016). CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-type dendritic cells as consolidation for multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT01995708.
83. 83 Kitawaki, T., Kadowaki, N., Fukunaga, K., Kasai, Y., Maekawa, T., Ohmori, K., Itoh, T., Shimizu, A., Kuzushima, K., Kondo, T., et al. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp. Hematol. 39 (2011), 424–433.e2.
84. 84 Nourizadeh, M., Masoumi, F., Memarian, A., Alimoghaddam, K., Moazzeni, S.M., Yaghmaie, M., Hadjati, J., In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC. Target. Oncol. 9 (2014), 225–237.
85. 85 Van Tendeloo, V.F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. USA 107 (2010), 13824–13829.
86. 86 Clinical Trials.gov. (2016). Efficacy study of dendritic cell vaccination in patients with acute myeloid leukemia in remission (WIDEA). https://clinicaltrials.gov/ct2/show/NCT01686334.
87. 87 Clinical Trials.gov. (2016). DC vaccination for postremission therapy in AML. https://clinicaltrials.gov/ct2/show/NCT01734304.
88. 88 Clinical Trials.gov. (2016). DC vaccination for post-remission therapy in AML https://clinicaltrials.gov/ct2/show/NCT02405338.
89. 89 Rosenblatt, J., Stone, R.M., Uhl, L., Neuberg, D., Joyce, R., Levine, J.D., Arnason, J., McMasters, M., Luptakova, K., Jain, S., et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci. Transl. Med., 8, 2016, 368ra171.
90. 90 Ni, M., Hoffmann, J.M., Schmitt, M., Schmitt, A., Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. Expert Opin. Biol. Ther. 16 (2016), 1113–1123.
91. 91 Luptakova, K., Rosenblatt, J., Glotzbecker, B., Mills, H., Stroopinsky, D., Kufe, T., Vasir, B., Arnason, J., Tzachanis, D., Zwicker, J.I., et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol. Immunother. 62 (2013), 39–49.
92. 92 Clinical Trials.gov. (2016). Blockade of PD-1 in conjunction with the dendritic cell/AML vaccine following chemotherapy induced remission. https://clinicaltrials.gov/ct2/show/NCT01096602.
93. 93 Nagle, S.J., Garfall, A.L., Stadtmauer, E.A., The promise of chimeric antigen receptor engineered T cells in the treatment of hematologic malignancies. Cancer J. 22 (2016), 27–33.
94. 94 de Haas, N., de Koning, C., Spilgies, L., de Vries, I.J., Hato, S.V., Improving cancer immunotherapy by targeting the STATe of MDSCs. OncoImmunology, 5, 2016, e1196312.
95. 95 Butt, A.Q., Mills, K.H., Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 33 (2014), 4623–4631.
96. 96 Stripecke, R., Cardoso, A.A., Pepper, K.A., Skelton, D.C., Yu, X.J., Mascarenhas, L., Weinberg, K.I., Nadler, L.M., Kohn, D.B., Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96 (2000), 1317–1326.
97. 97 Sundarasetty, B.S., Singh, V.K., Salguero, G., Geffers, R., Rickmann, M., Macke, L., Borchers, S., Figueiredo, C., Schambach, A., Gullberg, U., et al. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. Hum. Gene Ther. 24 (2013), 220–237.